Our Focus

Gannex, a wholly-owned company of Ascletis,is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three pre-clinical stage combination therapies. 


ASC40, a Global First-in-class, Oral FASN Inhibitor for NASH

ASC40英文.png



Efficacy and Safety of ASC40 Treatment in Patients with NASHimage.png



ASC41, an Oral THR-β Inhibitor for NASH

image.png

• Liver-targeted prodrug (ASC41) and active moiety (ASC41-A) is selective for THR-β 

• In two NASH animal models, at 1/10 dose of MGL-3196, ASC41 demonstrated the same improvement in liver steatosis, inflammation and fibrosis 

• A highly potent and selective THR-β agonist with anticipated human efficacious dose <10 mg QD

 Proprietary oral tablet formulation stable at room temperature and whose exposure is same as solution formulation in dogs 

• Topline data of Phase I safety, PK  and preliminary efficacy (LDL-C) in healthy volunteers with LDL-C > 110 mg/dL is expected to be available by the end of 2020 

• Combination opportunities with ASC42 (FXR) and ASC40 (FASN)



ASC42, an Oral FXR Inhibitor for NASH

image.png


• A novel non-steroidal, selective, potent FXR agonist 

• U.S. IND approved in October 2020 

• In two NASH animal models, ASC42 demonstrated the significant improvement in liver steatosis, inflammation, and fibrosis 

• An oral tablet formulation developed with proprietary therapy, stable at room temperature • Combination opportunities with ASC41 (THR-β) and ASC40 (FASN)